NCT06653348View on ClinicalTrials.gov

Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

August 1, 2026

Conditions
Ischemic StrokeTransient Ischemic Attack
Interventions
DRUG

Ticagrelor 60 + Aspirin

Ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month and then ticagrelor 60 mg BID plus ASA 80 mg daily until the end of month 6.

DRUG

Ticagrelor 90 + aspirin

ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month.

Trial Locations (1)

4817844718

RECRUITING

Mazandaran province, Sari,Iran, Sari

All Listed Sponsors
lead

Mazandaran University of Medical Sciences

OTHER